19941202
 Rhone-Poulenc Rorer gambles that genetics bet will pay off   By Moore, Stephen D, The Wall Street Journal,  Dec 2, 1994  Rhone-Poulenc Rorer, 68% owned by Rhone-Poulenc SA, has spent $300 million to date assembling the industry's biggest gene-therapy research network in the belief that gene therapy will contribute to the first big breakthrough coming in the treatment of cancer.   
